Patrick Donnelly

Management quantified LC replacement tailwind at 200-300bps and GC at 100bps, noted best market share data seen, driven by underinvestment, aged fleets, and favorable CapEx conditions.

Simon May confirmed strong H2 visibility with production schedules pointing to very strong Q3 YoY growth. Train C mechanical completion achieved in Q2, on schedule for spring 2027 go-live.

Adam confirmed low double-digit Q1 CDMO growth as expected. NASD 60% commercial programs, BioVectra ~33% commercial. Mid-teens full-year maintained. Simon added strong YoY order intake and good visibility to H2 revenue ramp.

Simon attributed LDG softness to weather and academic research markets, especially cell analysis with lower recurring revenue mix. Believes at or near bottom with NIH budgets plateauing. Adam added CDMO batch cadence also impacted LDG margin.

Padraig confirmed pharma 12%, biotech low twenties (low double digits ex CDMO). MFN tariff deals reducing uncertainty. ProIQ 50% single-quad growth in Q4. More typical year-end budget flush expected. Comprehensive.

Simon confirmed robust order book for nearly all of FY2026. Train C targeting go-live in 2027. Amortization and ramp dynamics to manage but well-covered in planning. Recent FDA siRNA approval validates modality confidence.

Rodney confirmed 100bps pricing contribution in Q3, accelerating from prior trends. Brief but direct quantification.

Padraig cited three tailwinds: Ignite gains, tariff mitigation, and volume leverage. Reiterated 100bps+ margin algorithm. Also highlighted Q4 expected 200bps sequential improvement vs flat Q2-Q3.

Padraig and Simon detailed NASD mix evolving to 60/40 commercial, BIOVECTRA GLP-1 scale-up success, clear line of sight to H2 double-digit NASD growth.

Padraig confirmed stable business with no pharma pull-forward, only consumables shift that nets out. Clear quantification of order trends.

Padraig and Simon confirmed strong NASD demand, unchanged guidance. Simon highlighted process qualification work positioning well for FY2026.

Padraig detailed $35M stimulus revenue, 50% win rate, ~50% pull-forward estimate. Bob confirmed second round not in guide as potential upside.

Padraig and Bob gave detailed breakdown of China trends, stimulus orders timing, and PFAS strength. Comprehensive response.

Padraig provided clear positioning on cycle timing and linked Infinity III to accelerating demand. Direct answer with specific color on competitive dynamics.

Birgit differentiated biotech demand: later-stage companies with IPO/M&A access showing clear uptick, but very early-stage startups remain sluggish with constrained seed funding. CRADL occupancy still below desired levels reflecting tepid early-stage demand.

Glenn outlined H2 margin drivers: over half from acquisitions/divestitures, plus lower corporate costs, cost savings, NHP timing normalization, and DSA cost relief. Quantified 2027 M&A/divestiture accretion at $0.50-$0.55 incremental to 2026.

Mike Nau confirmed compounding KF accretion: $0.25 in 2026 growing to approximately $0.60 in 2027 as insourcing ramps and sourcing costs normalize further.

Jim confirmed divestitures are on track for H1 2026 closure with interested parties. Proceeds will be deployed based on prevailing conditions across M&A, debt repayment, and share repurchases.

Foster highlighted proposals up for both pharma and biotech, cancellations declining, monthly book-to-bill improving for 3-4 months, and record October biotech funding as the second highest month ever.

Foster said need to see Q4 conclusion, Q1 start, and client 2026 budgets finalized before calling growth. Other factors include backlog nature, conversion speed, and study mix. Declined to predict 2026 growth rate.

Foster said DSA spot pricing is stable with competitors using price to compete; CRL distinguishes on science, quality and geographic proximity. Pease noted mix favorability in H1 enhanced price/mix dynamics but not counting on that continuing in H2.

Foster said hiring is catching up to current activity levels, not getting ahead. Declined to comment on 2026 growth but said trajectory is positive across client segments. Pharma moving slowly but nicely in right direction.

Foster expressed optimism but caution, saying they need to see sustained book-to-bill above 1x for several consecutive quarters before declaring a fundamental shift in the bookings trend.

Pease said DSA margin started strong in Q1, manufacturing margin should improve through the year, and refined consolidated margin guidance to minus 20-50 bps (from qualitative "modestly lower").

James expressed confidence DSA margins will not continue to contract, citing infrastructure rightsizing, technology/digitization, and eventual capacity fill as levers for meaningful improvement.

Flavia reiterated flat book-to-bill without fully explaining the apparent discrepancy, suggesting denominator differences or FX may explain the gap in the analyst's model.

Patrick described a shift toward automation and digitalization demand via OEMs and automation partners across regions.

Shawn gave price of ~3.5% in Q1, stepping down to ~2.5% for the full year as prior-year pricing laps.

Patrick acknowledged positive headlines but cited continued market uncertainty and longer deal cycles. Shawn added Q1 always has limited visibility and they expect gradual improvement through the year.

Shawn detailed: Q1 pricing 3.5%, full year 2.5%. Acquisitions ~1% H1, ~0.5% FY. Organic volume +1% FY but -1.5% Q1. Currency-neutral OP margin +60-70bps FY, reported up slightly. Q1 reported OP margin down ~90-100bps due to FX headwind.

Patrick detailed Europe as a tale of many cities: Southern Europe outperforming, Germany under significant energy cost pressure, Nordics disrupted by Novo Nordisk resizing. Better momentum in US than Europe. Leveraging Spinnaker tools to find hot segments.

Patrick noted PMIs still below 50 but automation and digitalization demand differentiating MTD. Portfolio competes well including in China. Onshoring benefits expected in future with digital capabilities and cybersecurity features.

Shawn provided H2 pricing at 3.5%, full year around 3% (slightly below prior 3%+ expectation due to surcharge pullbacks on rate changes). Swiss mitigation actions still being developed.

Shawn detailed Q3 guide: lab low single digit, core industrial and PI mid-to-high single digit. Americas mid-single digit, Europe low single digit, China flat. Industrial optimism key change.

Patrick noted project delays but maintained long-term confidence in automation demand from aging populations, workforce reduction, and onshoring needs.

Shawn detailed: China imports reduced to ~$50M (from under $100M), Mexico now higher than China but under $100M, total US imports from Europe/ROW ~$250M with significant Swiss portion.

Patrick acknowledged momentum in PI and pharma but maintained caution on tariff uncertainty and China. Emphasized lead generation execution to convert demand.

Shawn detailed gross margin +220bps in Q4 from volume, 2% pricing, SternDrive. Q1 down 220bps on delays but up 40bps adjusted. Full year up 20bps reported.

Jim clarified only 2 quarters of solid funding so far, right at the median 2-3 quarter lag. Base case is no meaningful uptick in Q4 but no worsening either. Kim added that early-stage funding was down while late-stage was up, explaining the surprise.

Kim described strong momentum especially in advanced therapeutics, validated by recent visit meeting government officials and customers. Direct market presence with well-connected team. No reason to believe growth will weaken.

Kim quantified headwind: 200bp Q1, 400bp Q2, 300bp Q3, 100-200bp Q4, then total reset in FY2027. Underlying growth ex-two customers was 30% under constrained conditions. 700+ customers, 85 in clinical, 6 in Phase III.

Kim described 6-month typical lag for funding to translate to spending. Reagent orders can come quicker while CapEx takes longer, creating a bell curve of 2 quarters plus-minus one. Biotech Q4 calendar funding increased significantly.

Kim reported Wilson Wolf had a flat quarter with TTM growth at low to mid-teens. EBITDA triggers will be tough given current conditions but deal structure ensures acquisition by end of calendar 2027 at 4.4x trailing 12-month revenue regardless.

Jim identified NIH budget resolution, pharma tariff/MFN clarity, and biotech funding recovery as the three key inflection catalysts. Noted biotech funding has shown encouraging uptick in recent months but cautioned two months does not make a trend.

Kim identified three China dynamics: government funding release (slight positive), stabilizing domestic market (China-for-China), and growing out-licensing of Chinese technologies globally as the true driver of sustained recovery to modest growth.

Jim confirmed Wilson Wolf delivered solid double-digit growth in the quarter. On track for a very strong calendar 2025 going into 2026.

Kim confirmed biotech at 30% of revenue was flattish in Q3, lagging large pharma recovery. Biotech spending described as sensitive to capital markets uncertainty leading to more frugal purchasing behavior expected to continue into Q4.

Jim noted FX created ~50bp margin headwind, narrowing 2H outlook to 50-150bp expansion vs prior 100-200bp. Significant sequential step-up driven by volume leverage, mix improvement, and organizational efficiencies.

Kim described continued commitment to life sciences research in China with increased government funding activity but acknowledged tough economic environment remains. Management still confident in Q3 positive growth.

Prahlad highlighted Lilly TuneLab partnership as strong launch path for Xynthetica. Max detailed software cadence: mid-single Q1, down ~20% Q2 on comps, high teens H2. SaaS ARR growth north of 30%, APV strong double digits.

Prahlad characterized academic/government as positively stable with positive mid-single-digit growth. Both instrument and reagent sides showing improvement. Building on optimism from Q4 trends.

Max noted reagents came in modestly below expectations as summer months were lighter, but overall lab activity continues to progress year over year.

Prahlad characterized 2-3% as prudent with upside from normalizing customer behavior. Max confirmed 28% baseline tied to 2-3% growth with restructuring actions already underway.

Max expects H2 reagents similar to H1 with pharma/biotech doing slightly better, academic/government still weak but more insulated.

Active pipeline but disciplined approach. No targets compelling enough financially. Share repurchases remain preferred deployment.

Max confirmed instruments more pressured, reagents slightly slower from academic headwinds but still solid, software stronger than prior low-double-digit guide.

Prahlad emphasized tariff planning began post-election, not in April. Max clarified exposure is Life Sciences products, not Diagnostics which is made in-China.

Max corrected that immunodiagnostics is assumed high-single-digit growth for 2025, driven by geographic expansion and autoimmune innovation.

Max explained normal seasonal cadence with Q1 lowest margins and highest tax rate, stepping down through the year.

Bob cited price acceleration above the 2-3% corridor, HVP incremental margins, and multiyear footprint/OpEx leverage with upside potential.

Eric described support across modalities, generics expansion out of Asia, new indications in late-stage development, and orals expanding the market.

Bob expects Q2 margins roughly in line with Q1 at 21.4%, with second-half expansion. Full year about 50 additional basis points improvement versus prior guide. Mix shift, operational execution, and volume leverage all contributing.

Eric highlighted biologics/biosimilars growing 26%, mostly from commercialized drugs. Annex-1 projects up 66% YoY. ASP and margin improvement from conversions. Bob confirmed this is a continuation of H2 2025 momentum with demand still outstripping supply.

Bob attributed margin expansion to HVP utilization, mix shift, and continued positive pricing plus Annex-1 conversion and SmartDose removal. Eric explained multidose pen vs auto-injector economics differ but transition would take multiple years given installed capacity investments.

Eric confirmed late-stage replacement customer discussions with stronger expected economics. Engineering fees during transition will provide interim revenue. Bob identified medium-to-longer-term footprint optimization and consolidation opportunities beyond 2026.

Bernard explained Q3 margin step-down from seasonality (European plant shutdowns, lower absorption), plus onboarding headcount with training impact on productivity. Slightly lower margins in second half vs Q2 is typical seasonality.

Eric confirmed order patterns support second-half HVP acceleration, with pharma destocking subsided and biologics ramping.

Eric acknowledged oral GLP-1 impact but emphasized majority delivery will remain injectable; investments are ring-fenced with take-or-pay contracts.

Bernard outlined Q1 as the trough with progressive margin improvement driven by HVP growth and destocking normalization through the year.